Bayer pharma chief signals pause on major acquisitions, focus on internal growth
Bayer’s pharmaceuticals division is signaling a shift in strategy, with its chief, Stefan Oelrich, indicating that large-scale acquisitions are unlikely in the near future. Instead, the focus will be on … Read More
